New Brunswick, New Jersey
July 3, 2002

Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) today announced that it posted the Company's annual Letter to Stockholders and a Research and Development update on its Company web site at www.senesco.com. The Letter to Stockholders reviews corporate events that occurred during the past fiscal year and outlines key goals and objectives for the upcoming fiscal year. Specifically, the letter addresses securing additional long-term equity financing, Senesco's new listing on the American Stock Exchange, its license agreements with Harris Moran Seed Company and ArborGen, LLC, and its joint venture with Rahan Meristem.

The Company's R&D Letter outlines the expansion of its ongoing research and development programs. As the letter indicates, the Company's research has yielded new findings, which we believe will expand opportunities to apply the Company's gene technology. The Company's research has shown that the DHS and Factor 5A genes regulate apoptosis in animal and human cells, while pre-clinical studies have shown that the Factor 5A gene is able to kill cancer cells. The letter also discusses the potential
applicability of Senesco's technology in targeting major diseases such as tumors, heart disease and glaucoma.

Senesco takes its name from the scientific term for the aging of cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that Senesco's technology can be used to develop superior strains of crops by delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partner's products. Senesco is headquartered in New Brunswick, New Jersey, and has research laboratories at the University of Waterloo in Ontario, Canada.